GRFSNasdaqPharmaceutical PreparationsAlso trades as GIFLF, GIFOF, GIKLY
Grifols SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 17, 2026
$7.64+0.00 (0.00%)
Close on Oct 19, 2026
Grifols SA revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma | €6.49B | €6.14B | €5.56B | €5.01B | €3.81B | €4.24B | – | – | – | – | 86.2% | +5.6% |
| Diagnostic | €640.00M | €645.00M | €670.00M | €671.29M | €779.11M | €775.89M | €733.60M | €702.27M | €732.37M | €691.70M | 8.5% | -0.8% |
| Others | €243.00M | €208.00M | €204.00M | – | – | – | – | – | – | – | 3.2% | +16.8% |
| Bio Supplies | €154.00M | €216.00M | €160.00M | €146.08M | €115.81M | €133.22M | €266.54M | €167.00M | €66.79M | €57.24M | 2.0% | -28.7% |
| Others | – | €209.23M | €203.45M | €250.17M | €266.46M | €222.52M | €22.82M | €22.45M | €18.26M | €34.60M | – | – |
| Bioscience | – | – | – | – | €3.81B | €4.24B | €3.99B | €3.52B | €3.43B | €3.20B | – | – |
| Hospital | – | – | – | – | €141.19M | €118.68M | €134.44M | €119.45M | €105.65M | €102.25M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma | €1.40B | €1.27B | €886.00M | €791.34M | €681.93M | €967.42M | – | – | – | – | +10.2% |
| Diagnostic | €96.00M | €109.00M | €111.00M | €129.97M | €152.95M | €215.79M | €215.83M | €215.99M | €248.08M | €97.32M | -11.9% |
| Bio Supplies | €40.00M | €48.00M | €44.00M | €114.40M | €39.90M | €36.14M | €16.25M | €36.82M | €35.60M | €33.79M | -16.7% |
| Others | -€42.00M | €38.00M | €8.00M | – | – | – | – | – | – | – | -210.5% |
| Others | – | – | €6.63M | -€46.81M | -€83.48M | -€43.96M | €1.28M | €19.79M | -€9.63M | €44.32M | – |
| Bioscience | – | – | – | – | €658.69M | €949.99M | €1.08B | €902.40M | €985.50M | €913.84M | – |
| Hospital | – | – | – | – | -€7.74M | -€12.50M | -€8.67M | -€12.59M | -€9.77M | -€8.77M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Haemoderivatives | €6.49B | €6.14B | €5.56B | €5.01B | €3.81B | €4.24B | €3.99B | €3.52B | €3.43B | €3.23B | 86.2% | +5.6% |
| Transfusional medicine | €623.00M | €625.00M | €648.00M | €640.60M | €712.24M | €714.16M | €680.77M | €650.18M | €679.69M | €640.44M | 8.3% | -0.3% |
| Others | €243.00M | €208.00M | €204.00M | €250.17M | €266.46M | €222.52M | €22.82M | €22.45M | €18.26M | €34.60M | 3.2% | +16.8% |
| Bio supplies | €154.00M | €216.00M | €160.00M | €146.08M | €115.81M | €133.22M | €266.54M | €167.00M | €66.79M | €24.39M | 2.0% | -28.7% |
| Other diagnostic | €17.00M | €20.00M | €22.00M | €21.74M | €23.63M | €27.63M | €19.94M | €19.80M | €23.38M | €23.54M | 0.2% | -15.0% |
| Fluid therapy and nutrition | – | – | – | – | €46.67M | €41.36M | €47.68M | €52.57M | €47.70M | €46.21M | – | – |
| Hospital supplies | – | – | – | – | €70.22M | €58.30M | €67.49M | €58.01M | €52.47M | €52.37M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| USA and Canada | €4.25B | €4.09B | €3.90B | €3.86B | €3.15B | €3.60B | €3.39B | €2.97B | €2.90B | €2.71B | 56.5% | +4.1% |
| Rest of the world | €1.66B | €1.63B | €1.44B | €1.18B | €872.12M | €905.80M | €851.22M | €768.08M | €734.59M | €690.76M | 22.0% | +1.9% |
| Rest of European Union | €1.20B | €1.08B | €893.00M | €711.58M | €544.04M | €495.32M | €588.38M | €479.31M | €444.09M | €426.22M | 15.9% | +11.2% |
| Spain | €418.00M | €423.00M | €363.00M | €320.63M | €362.41M | €339.17M | €268.29M | €264.91M | €242.89M | €225.27M | 5.6% | -1.2% |
| Spain | – | – | €362.88M | €320.63M | €362.41M | €339.17M | €268.29M | €264.91M | €242.89M | €225.27M | – | – |
| European Union | – | – | €893.05M | €711.58M | €544.04M | €495.32M | €588.38M | €479.31M | €444.09M | €426.22M | – | – |
| USA and Canada | – | – | €3.90B | €3.86B | €3.15B | €3.60B | €3.39B | €2.97B | €2.90B | €2.71B | – | – |
From the segment and revenue-disaggregation notes of Grifols's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.